Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and/or lymphopenia (RELEASE NCT04578210)
Cristina Ferreras, Clara Hernández-Blanco, Alejandro Martín‐Quirós, Karima Al‐Akioui‐Sanz, Marta Mora-Rillo, Fátima Ibáñez, Mariana Díaz‐Almirón, Jordi Cano-Ochando, Daniel Lozano‐Ojalvo, María Jiménez-González, Rosa Goterris, Elena Sánchez‐Zapardiel, Raquel de Paz, Pilar Guerra‐García, Javier Queiruga‐Parada, P Tauber Molina, María Luisa Briones, Beatriz Ruz-Caracuel, Alberto M. Borobia, Antonio J. Carcas, Dolores Planelles, José L. Vicário, Miguel Ángel Moreno, A. Balas, Marta Llano, Andrea Llorente, Álvaro del Balzo, Carlos Cañada, Miguel Ángel García, María Elena Calvin, Isabel Arenas, Rebeca Pérez de Diego, Cristina Eguizábal, Bernat Soria, Carlos Solano, Antonio Pérez‐Martínez
Topics & Concepts
MedicineSevere acute respiratory syndromeInternal medicineAdverse effectRandomized controlled trialImmunologyPopulationViral loadCytokine release syndromeT cellVirusDiseaseCoronavirus disease 2019 (COVID-19)Immune systemChimeric antigen receptorInfectious disease (medical specialty)Environmental healthSARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinationsCOVID-19 Clinical Research Studies